Zenas BioPharma (ZBIO) to Release Quarterly Earnings on Tuesday

Zenas BioPharma (NASDAQ:ZBIO) is expected to release its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Zenas BioPharma to announce earnings of ($1.12) per share and revenue of $15.00 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 12:30 PM ET.

Zenas BioPharma (NASDAQ:ZBIO) last announced its earnings results on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.01. During the same period in the prior year, the firm posted ($0.80) EPS. On average, analysts expect Zenas BioPharma to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Zenas BioPharma Price Performance

ZBIO traded up $0.37 during trading on Tuesday, reaching $31.50. The stock had a trading volume of 131,253 shares, compared to its average volume of 849,232. The firm has a market capitalization of $1.99 billion, a price-to-earnings ratio of -3.72 and a beta of -1.03. The company has a quick ratio of 11.94, a current ratio of 11.94 and a debt-to-equity ratio of 1.04. Zenas BioPharma has a 1-year low of $13.50 and a 1-year high of $44.60. The stock has a 50 day moving average of $24.55 and a two-hundred day moving average of $22.71.

Insider Transactions at Zenas BioPharma

In related news, CEO Leon O. Moulder, Jr. acquired 60,000 shares of the business’s stock in a transaction on Monday, May 18th. The shares were purchased at an average price of $16.88 per share, for a total transaction of $1,012,800.00. Following the acquisition, the chief executive officer owned 96,928 shares in the company, valued at approximately $1,636,144.64. This represents a 162.48% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 22.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Virtus Investment Advisers LLC purchased a new position in shares of Zenas BioPharma during the fourth quarter valued at $238,000. Janus Henderson Group PLC acquired a new position in Zenas BioPharma during the fourth quarter valued at $287,000. Mariner LLC purchased a new stake in Zenas BioPharma in the 4th quarter worth about $279,000. Marshall Wace LLP purchased a new stake in Zenas BioPharma in the 4th quarter worth about $258,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Zenas BioPharma during the 4th quarter worth about $227,000.

Analysts Set New Price Targets

A number of research firms have recently commented on ZBIO. Weiss Ratings downgraded Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 9th. Citigroup restated a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. HC Wainwright reissued a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Finally, Zacks Research upgraded shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Zenas BioPharma currently has an average rating of “Moderate Buy” and a consensus price target of $44.29.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.